For the Inventor, By the Inventor

Enter assignee name

Santen Pharmaceutical Co., Ltd.

USPTO Granted Patents = 282

CIPO Patents = 17

EPO Patents = 92

Trademarks = 24

Forward Citations = 1,322

Loading Chart...

Loading Chart...

301 inventors (with patents filed for the assignee):

Tadashi Iso (33 out of 33 patents)

Masayuki Oya (27 out of 32 patents)

Yoichi Kawashima (25 out of 27 patents)

4. Shiro Mita (23 out of 24 patents)

5. Minoru Yamamoto (19 out of 20 patents)

6. Masatsugu Nakamura (19 out of 40 patents)

7. Kenji Kawashima (18 out of 19 patents)

8. Masakazu Ban (18 out of 18 patents)

9. Hiroshi Suhara (18 out of 18 patents)

10. Jun-ichi Iwao (18 out of 18 patents)

11. Masatomo Kato (17 out of 17 patents)

12. Jensen Buck (17 out of 19 patents)

13. Anand Doraiswamy (17 out of 22 patents)

14. Mamoru Matsuda (15 out of 15 patents)

15. Miwa Takai (15 out of 15 patents)

Core Competencies:

Pharmaceutical Formulations

Pyridylaminoacetic Acid

Dry Eye Treatment

Glaucoma Treatment

Meibomian Dysfunction

Anti-VEGF Antibody

Ophthalmic Solutions

Presbyopia Treatment

Myopia Prevention

Sustained-Release Composition

Intratumoral Administration

Ocular Hypertension

282 patents: Sort by Forward Citations

1. 12510536 - Method for changing condition of eyelid of hairless animal (2025-12-30),

2. 12295946 - Pharmaceutical formulations comprising a pyridylaminoacetic acid compound (2025-05-13),

3. 12290511 - Pharmaceutical preparation containing pyridyl aminoacetic acid compound (2025-05-06),

4. 12290497 - Agent containing 4-phenylbutyrate, for preventing or treating presbyopia (2025-05-06),

5. 12201602 - Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor (2025-01-21),

6. 12005063 - Medicament for preventing and/or treating dry eye (2024-06-11),

7. 11974994 - Agent for treating or preventing glaucoma including a sulfonamide compound and another drug (2024-05-07),

8. 11951098 - Therapeutic agent for meibomian dysfunction (2024-04-09),

9. 11872271 - High-affinity anti-VEGF antibody KLHa505 (2024-01-16),

10. 11793798 - Pharmaceutical formulations comprising a pyridylaminoacetic acid compound (2023-10-24),

11. 11707577 - Accurate, precise microliter dosing syringe (2023-07-25),

12. 11666563 - Pharmaceutical preparation containing pyridyl aminoacetic acid compound (2023-06-06),

13. 11642350 - Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient (2023-05-09),

14. 11612590 - Therapeutic agent for meibomian dysfunction (2023-03-28),

15. 11446273 - Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor (2022-09-20),

Santen Pharmaceutical Co., Ltd. is a globally recognized pharmaceutical company in Japan. They specialize in the research, development, and manufacturing of ophthalmic products and medical devices. Santen is dedicated to improving vision health and providing innovative solutions for various eye conditions and diseases. With a strong focus on research and development, Santen continues to drive advancements in ophthalmology worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

282 Patents

#60 in Osaka

#542 in Japan

#3,049 in the World

Santen Pharmaceutical Co., Ltd.

Forward Citations = 1,322

301 inventors:

Tadashi Iso (33 out of 33 patents)

Masayuki Oya (27 out of 32 patents)

Yoichi Kawashima (25 out of 27 patents)

4. Shiro Mita (23 out of 24 patents)

5. Minoru Yamamoto (19 out of 20 patents)

Please report any incorrect information to support@idiyas.com

Loading…